318 related articles for article (PubMed ID: 24077351)
1. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
Gajjar A; Stewart CF; Ellison DW; Kaste S; Kun LE; Packer RJ; Goldman S; Chintagumpala M; Wallace D; Takebe N; Boyett JM; Gilbertson RJ; Curran T
Clin Cancer Res; 2013 Nov; 19(22):6305-12. PubMed ID: 24077351
[TBL] [Abstract][Full Text] [Related]
2. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
3. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
Lorusso PM; Jimeno A; Dy G; Adjei A; Berlin J; Leichman L; Low JA; Colburn D; Chang I; Cheeti S; Jin JY; Graham RA
Clin Cancer Res; 2011 Sep; 17(17):5774-82. PubMed ID: 21753154
[TBL] [Abstract][Full Text] [Related]
5. MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
Frappaz D; Barritault M; Montané L; Laigle-Donadey F; Chinot O; Le Rhun E; Bonneville-Levard A; Hottinger AF; Meyronnet D; Bidaux AS; Garin G; Pérol D
Neuro Oncol; 2021 Nov; 23(11):1949-1960. PubMed ID: 33825892
[TBL] [Abstract][Full Text] [Related]
6. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
De Smaele E; Ferretti E; Gulino A
Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
[TBL] [Abstract][Full Text] [Related]
7. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
Robinson GW; Orr BA; Wu G; Gururangan S; Lin T; Qaddoumi I; Packer RJ; Goldman S; Prados MD; Desjardins A; Chintagumpala M; Takebe N; Kaste SC; Rusch M; Allen SJ; Onar-Thomas A; Stewart CF; Fouladi M; Boyett JM; Gilbertson RJ; Curran T; Ellison DW; Gajjar A
J Clin Oncol; 2015 Aug; 33(24):2646-54. PubMed ID: 26169613
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
[TBL] [Abstract][Full Text] [Related]
9. SHH inhibitors for the treatment of medulloblastoma.
Samkari A; White J; Packer R
Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
LoRusso PM; Rudin CM; Reddy JC; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Chang I; Darbonne WC; Graham RA; Zerivitz KL; Low JA; Von Hoff DD
Clin Cancer Res; 2011 Apr; 17(8):2502-11. PubMed ID: 21300762
[TBL] [Abstract][Full Text] [Related]
11. Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases.
Climans SA; Macdonald DR; Sutherland DE; Mason WP
BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33122230
[TBL] [Abstract][Full Text] [Related]
12. Vismodegib and Physeal Closure in a Pediatric Patient.
Lucas JT; Wright KD
Pediatr Blood Cancer; 2016 Nov; 63(11):2058. PubMed ID: 26864592
[No Abstract] [Full Text] [Related]
13. Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.
Kieran MW; Chisholm J; Casanova M; Brandes AA; Aerts I; Bouffet E; Bailey S; Leary S; MacDonald TJ; Mechinaud F; Cohen KJ; Riccardi R; Mason W; Hargrave D; Kalambakas S; Deshpande P; Tai F; Hurh E; Geoerger B
Neuro Oncol; 2017 Oct; 19(11):1542-1552. PubMed ID: 28605510
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
Sharma MR; Karrison TG; Kell B; Wu K; Turcich M; Geary D; Kang SP; Takebe N; Graham RA; Maitland ML; Schilsky RL; Ratain MJ; Cohen EE
Clin Cancer Res; 2013 Jun; 19(11):3059-67. PubMed ID: 23553850
[TBL] [Abstract][Full Text] [Related]
16. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
17. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
[TBL] [Abstract][Full Text] [Related]
18. Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma.
Asklund T; Henriksson R; Axelsson J; Bergström Å; Kasper M; Ögren M; Toftgård R; Riklund KÅ
Acta Oncol; 2013 May; 52(4):862-6. PubMed ID: 23013267
[No Abstract] [Full Text] [Related]
19. Vismodegib in basal cell carcinoma.
Amaria RN; Bowles DW; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
[TBL] [Abstract][Full Text] [Related]
20. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
